Erstlinientherapie beim metastasierten hormonsensitiven Prostatakarzinom (mHSPC)First-line treatment of metastatic hormone-sensitive prostate cancer (mHSPC)

被引：0

作者：

H. Rexer

S. Feyerabend

M. Graefen

机构：

[1] AUO Geschäftsstelle,

[2] Studienpraxis Nürtingen,undefined

[3] Organgruppe Prostatakarzinom der Arbeitsgemeinschaft Urologische Onkologie in der Deutschen Krebsgesellschaft e. V.,undefined

来源：

Forum | 2023年 / 38卷 / 3期

关键词：

D O I：

10.1007/s12312-023-01201-z

中图分类号：

学科分类号：

摘要：

引用

页码：238 / 239

页数：1

共 50 条

[1] AUO First-line Therapy for metastatic hormone-sensitive Prostate Cancer (mHSPC)
Rexer, H.
Feyerabend, S.
Graefen, M.
UROLOGIE, 2023, 62 (04): : 441 - 442
[2] Metastatic Hormone-Sensitive Prostate Cancer (mHSPC): Advances and Treatment Strategies in the First-Line Setting
Kenrick Ng
Shievon Smith
Jonathan Shamash
Oncology and Therapy, 2020, 8 : 209 - 230
[3] Metastatic Hormone-Sensitive Prostate Cancer (mHSPC): Advances and Treatment Strategies in the First-Line Setting
Ng, Kenrick
Smith, Shievon
Shamash, Jonathan
ONCOLOGY AND THERAPY, 2020, 8 (02) : 209 - 230
[4] Recent developments in the treatment of metastatic hormone-sensitive prostate cancer (mHSPC)
Schwentner, Christian
AKTUELLE UROLOGIE, 2022, 53 (01) : 31 - 36
[5] Management of Metastatic Hormone-Sensitive Prostate Cancer (mHSPC): an Evolving Treatment Paradigm
Weiner, Adam B.
Nettey, Oluwarotimi S.
Morgans, Alicia K.
CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2019, 20 (09)
[6] Management of Metastatic Hormone-Sensitive Prostate Cancer (mHSPC): an Evolving Treatment Paradigm
Adam B. Weiner
Oluwarotimi S. Nettey
Alicia K. Morgans
Current Treatment Options in Oncology, 2019, 20
[7] TITAN study: evaluation of apalutamide in patients with metastatic hormone-sensitive prostate cancer - Treatment of metastatic hormone-sensitive prostate cancer (mHSPC)
Merseburger, Axel S.
Suttmann, Henrik
AKTUELLE UROLOGIE, 2021, 52 (02) : 155 - 160
[8] Use of abiraterone for patients with metastatic hormone-sensitive prostate cancer (mHSPC)
Cathomas, R.
ONCOLOGY RESEARCH AND TREATMENT, 2018, 41 : 130 - 130
[9] DISEASE BURDEN OF METASTATIC HORMONE-SENSITIVE PROSTATE CANCER (MHSPC) IN CHINA
Yu, M.
Duan, X.
Wang, J.
Zhang, X. J.
Yu, F.
VALUE IN HEALTH, 2021, 24 : S39 - S40
[10] Kombinierte Systemtherapie beim metastasierten hormonsensitiven Prostatakarzinom: Was? Wann? Bei wem?Combination therapy for metastatic hormone-sensitive prostate cancer: What? When? For whom?
C. Thomas
C.‑H. Ohlmann
Der Urologe, 2020, 59 (6): : 665 - 672

← 1 2 3 4 5 →